BioDelivery's opioid treatment wins FDA approval

Reuters

Mon, Oct 26, 2015, 6:15 AM

Oct 26 (Reuters) - The U.S. Food and Drug Administration has approved BioDelivery Sciences International Inc's opioid treatment for chronic pain, the company said on Monday.

Endo International Plc licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012.

Belbuca is an opioid film patch and aims to treat patients with chronic pain who need around-the-clock treatment and for whom current alternatives do not suffice.

(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel)

Mark Zuckerberg got $24.4 million in ‘other compensation’ in 2023—but Meta also treated staff well, with the median employee making $379,000
On paper, Mark Zuckerberg is Meta’s lowest-paid employee, with a $1 dollar salary and no bonus.
Fortune•1d ago
$433 Billion Gone! One Stock Loses More Value Than Tesla
Tesla's loss of $328.3 billion this year in stock value certainly hurts. But it's only the second-largest market value loss in the S&P 500.
Investor's Business Daily•1d ago
Southwest will limit hiring and drop 4 airports after loss. American Airlines posts 1Q loss as well
Southwest Airlines will limit hiring and stop flying to four airports as it copes with weak financial results and delays in getting new planes from Boeing. Both Southwest and American Airlines reported first-quarter losses Thursday. CEO Robert Jordan said the airline was reacting quickly “to address our financial underperformance," including by slowing down hiring and asking employees to take time off.
Associated Press Finance•2h ago
Stock market today: US futures tumble after Meta's reality check, soft GDP print
Meta's AI reality check has dented hopes for a Big Tech revival for stocks, with a GDP update waiting in the wings.
Yahoo Finance•37m ago
The Vanguard 500 Index Fund Is Great, But Another Vanguard ETF Has Outperformed It the Past Decade
This growth ETF has nicely outperformed the S&P 500 since its inception.
Motley Fool•3h ago
Bitcoin Just Did Something It Has Only Done 3 Times Before. The Cryptocurrency Usually Does This Next.
Bitcoin block subsidies were recently reduced by half for the fourth time in history, and halving events have always led to significant price appreciation.
Motley Fool•4h ago
One Member of Congress Is Going Against the Grain and Selling This Skyrocketing Stock-Split Stock
One of Capitol Hill's most-active stock traders is sending a company with well-defined competitive advantages -- that also happens to be on the verge of its first-ever stock split -- to the chopping block.
Motley Fool•4h ago
China's Temu Takes Over 17% Of US Market Share, Cutting Jobs From American Amazon And Decimating Small Businesses
With rising inflation, American consumers are increasingly turning to the Chinese e-commerce platform Temu for their shopping needs. With its enticing tagline “Shop like a billionaire,” Temu has captured 17% of the U.S. market share, posing a challenge to traditional American retailers such as Amazon.com Inc., Dollar Tree Inc. and Five Below Inc. The rise highlights the lucrative and disruptive nature of startups. Owned and operated by PDD Holdings Inc. (NASDAQ:PDD), Temu offers a wide range of
Benzinga•17h ago
I Have $900k in a Roth IRA and Would Receive $2,200 Monthly From Social Security. Can I Retire at 66?
Imagine that you have $900,000 in a Roth IRA and collect another $2,200 per month in Social Security. Can you afford to retire at age 66? A good way to answer this question is to start with your budget. What do you expect to spend on essentials, like housing and fixed monthly expenses, and what […] The post I Have $900k in a Roth IRA and Would Receive $2,200 Monthly From Social Security. Can I Retire at 66? appeared first on SmartReads by SmartAsset.
SmartAsset•2h ago
3 Absurdly Cheap Stocks to Buy and Hold for Years
These stocks all deserve to be trading at far higher prices, and it may not be too long before they start to rally.
Motley Fool•3h ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioDelivery's opioid treatment wins FDA approval

Recommended Stories

Mark Zuckerberg got $24.4 million in ‘other compensation’ in 2023—but Meta also treated staff well, with the median employee making $379,000

$433 Billion Gone! One Stock Loses More Value Than Tesla

Southwest will limit hiring and drop 4 airports after loss. American Airlines posts 1Q loss as well

Stock market today: US futures tumble after Meta's reality check, soft GDP print

The Vanguard 500 Index Fund Is Great, But Another Vanguard ETF Has Outperformed It the Past Decade

Bitcoin Just Did Something It Has Only Done 3 Times Before. The Cryptocurrency Usually Does This Next.

One Member of Congress Is Going Against the Grain and Selling This Skyrocketing Stock-Split Stock

China's Temu Takes Over 17% Of US Market Share, Cutting Jobs From American Amazon And Decimating Small Businesses

I Have $900k in a Roth IRA and Would Receive $2,200 Monthly From Social Security. Can I Retire at 66?

3 Absurdly Cheap Stocks to Buy and Hold for Years